G1 Therapeutics (GTHX)
(Real Time Quote from BATS)
$7.08 USD
-0.01 (-0.14%)
Updated Aug 12, 2024 12:34 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GTHX 7.08 -0.01(-0.14%)
Will GTHX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GTHX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GTHX
G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates
Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates
GTHX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Acadia Pharmaceuticals (ACAD) Beats Q2 Earnings and Revenue Estimates
G1 Therapeutics (GTHX) Reports Q1 Loss, Lags Revenue Estimates
G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates
Other News for GTHX
Largest borrow rate increases among liquid names
Wall Street Breakfast: The Week Ahead
Biotech Alert: Searches spiking for these stocks today
G1 Therapeutics reports Q2 EPS (10c), consensus (16c)
Catalyst Watch: Eyes on Walmart earnings, the July CPI print, and 13F filings